CC0 PUBLIC RECORD GRAPH Every score & timeline item links directly to its underlying U.S. FDA record (openFDA, ORA FOIA Reading Room, DECRS & OASIS).
Scoring Formula v2.0 & Legal Guardrails REST API v1
FG
GMPGraphv2.0
Global FDA Facility Graph & Co-Packer Intelligence
21 CFR Encyclopedia → FD&C Act Sec. 605 / MoCRA Serious Adverse Event
FD&C Act Sec. 605 / MoCRA Serious Adverse Event Cosmetics (MoCRA) 144 Annual Form 483 Citations

FD&C Act Sec. 605 / MoCRA Serious Adverse Event — Failure to maintain 15-day Serious Adverse Event reporting & label contact address

Plain-English Risk Theme: CAPA, Out-of-Specification (OOS) & Complaint Investigations · Official eCFR Text ↗
🛡️ Test Your SOP Against FD&C Act Sec. 605 / MoCRA Serious Adverse Event →
Official FDA Inspectional Observation Template
"Responsible person failed to maintain records of adverse events and submit serious adverse event reports within 15 business days, or product label omitted domestic address, phone number, or electronic contact information for adverse event receipt."
Plain-English Brand & QA Translation
Failure to thoroughly investigate unexplained batch discrepancies, Out-of-Specification lab results, or consumer complaints/adverse events and document root-cause Corrective and Preventive Actions (CAPA).
🚨 Why 15-Day Form 483 Responses Fail on FD&C Act Sec. 605 / MoCRA Serious Adverse Event:
FDA routinely rejects 15-day Form 483 responses for FD&C Act Sec. 605 / MoCRA Serious Adverse Event when a facility merely states 'we revised our SOP and retrained personnel' without attaching: (1) the signed, effective-dated SOP, (2) photographic or batch-log proof of implementation, and (3) a retrospective impact assessment of all commercial lots manufactured over the prior 24 months within expiry.
✅ Standard 15-Day CAPA Remediation Blueprint:
  1. Immediate Containment (Days 1–3): Place affected raw materials or in-process lots on QA Hold and open formal CAPA under FD&C Act Sec. 605 / MoCRA Serious Adverse Event.
  2. Systemic Root-Cause & SOP Overhaul (Days 4–10): Deploy a closed-loop CAPA and OOS investigation SOP requiring root-cause determination within 30 business days, impact assessment on distributed lots, and effectiveness checks.
  3. Retrospective Lot Review & Effectiveness Check (Days 11–15): Test retention samples of distributed lots and schedule a 30/60/90-day QA audit to prove sustained compliance.

Copy-Paste Compliant SOP Clause Template (FD&C Act Sec. 605 / MoCRA Serious Adverse Event)

FREE AUDIT-READY BOILERPLATE 
STANDARD OPERATING PROCEDURE — COMPLIANCE CLAUSE FD&C Act Sec. 605 / MoCRA Serious Adverse Event
1. PURPOSE: Establish mandatory cGMP controls satisfying FD&C Act Sec. 605 / MoCRA Serious Adverse Event (Failure to maintain 15-day Serious Adverse Event reporting & label contact address).
2. REQUIREMENT: Deploy a closed-loop CAPA and OOS investigation SOP requiring root-cause determination within 30 business days, impact assessment on distributed lots, and effectiveness checks.
3. QA VERIFICATION & SIGN-OFF: Dual independent verification by Production and Quality Assurance Unit (QAU) is required prior to batch release. Any deviation or Out-of-Specification (OOS) result triggers a formal CAPA investigation within 24 hours.

FDA Investigators Who Frequently Cite FD&C Act Sec. 605 / MoCRA Serious Adverse Event

Elena R. Rostova (Pacific Southwest Division (Los Angeles District)) →

Published Form 483s Citing FD&C Act Sec. 605 / MoCRA Serious Adverse Event

Read 483 Breakdown →
Dr. J Skinclinic, Inc Issued 2026-03-23
Read 483 Breakdown →
COSMETIC LABORATORY INC Issued 2026-03-10
Read 483 Breakdown →
Dreyer's Grand Ice Cream, Inc. Issued 2026-02-20
Read 483 Breakdown →